Zotepine is an atypical antipsychotic drug indicated for acute and chronic schizophrenia. It has been used in Germany since 1990 and Japan since 1982. Zotepine is not approved for use in the United States, United Kingdom, Australia, Canada or New Zealand. It is a tricyclic thienobenzodiazepine derivative that exhibits antagonist activity at dopamine D2 and serotonin 5-HT2A receptors with additional affinity for alpha1-adrenergic and H1 histamine receptors and modest anticholinergic properties. Administered orally as immediate-release tablets, zotepine is well absorbed and extensively metabolized in the liver primarily via CYP enzymes to N-desmethyl and hydroxylated metabolites, with a terminal plasma half-life commonly reported in the range of about 8 to 12 hours. Clinical utility is based on reduction of positive psychotic symptoms with dose-dependent effects on motor side effects and sedation. Pharmacokinetic and safety monitoring considerations include hepatic metabolism, potential drug interactions with CYP modulators, metabolic parameter monitoring, and cardiovascular assessment as clinically indicated.
API quality control for zotepine applies validated chromatographic and mass spectrometric methods to monitor related substances, degradation products, residual solvents and elemental impurities. Typical specified related compounds include N-desmethyl-zotepine, zotepine N-oxide, mono- and di-hydroxylated isomers and a ring-opened degradant, each of which is identified and quantified during release testing. Typical acceptance criteria applied in manufacturing specifications are individual specified impurities not greater than 0.10% w/w, reporting threshold and identification for impurities at or above 0.05% w/w in accordance with ICH Q3A and Q3B guidance, and a total impurities limit typically not greater than 0.50% w/w. Known related compounds such as N-desmethyl-zotepine and N-oxide are commonly controlled to limits at or below 0.10% each. Residual solvents and elemental impurities are controlled to limits defined in ICH Q3C and Q3D.
Zotepine is used as an antipsychotic for the treatment of acute and chronic schizophrenia, prescribed where available to manage psychotic symptoms when clinically appropriate, with dosing and monitoring adjusted for efficacy and tolerability.
Zotepine is the international nonproprietary name, and it may be marketed under different proprietary brand names in countries where it is available; it is also described chemically as a thienobenzodiazepine derivative and has commonly reported metabolite names such as N-desmethyl-zotepine.
